edrecolomab
mAbexperimental
Edrecolomab is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 1995 (NCT00002664)
Timeline
Indications
Mechanism of action
- Epithelial cell adhesion moleculeBINDING AGENT
EPCAM binding agent
- Epithelial cell adhesion moleculeCROSS-LINKING AGENT
EPCAM cross-linking agent
- Epithelial cell adhesion moleculeINHIBITOR
EPCAM inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEdrecolomab ↗
- ChEMBLCHEMBL2109415 ↗
- ChEMBLCHEMBL2108955 ↗
Also known as
- 17-1a
- c-1
- c-1
- edrecolomab
- edrecolomab
- edrecolomab
- mab 17-1a
- mab 17-1a
- mab-17-1a
- monoclonal antibody 17-1a
- panorex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00309517 | Phase 3 | Jul 1, 1997 | Austrian Breast and Colorectal Cancer Group |
| NCT00002968 | Phase 3 | May 1, 1997 | Cancer and Leukemia Group B (CALGB), National Cancer Institute (NCI) |
| NCT00002664 | Phase 2 | Jul 1, 1995 | George Washington University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Austrian Breast and Colorectal Cancer Group | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 1997 |
| George Washington University | Academic/Hospital | 1 | 1 | 1 | 1995 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1997 |
4 organizations
Page 1 / 1